A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison
Anna Palmer, Timothy Papaluca, Mark Stoove, Rebecca Winter, Alisa Pedrana, Margaret Hellard, David Wilson, Alexander Thompson, Nick Scott
INTERNATIONAL JOURNAL OF DRUG POLICY | ELSEVIER | Published : 2021
BACKGROUND: Hepatitis C is highly prevalent among prisoners. The simplicity of direct-acting antiviral (DAA) treatment for hepatitis C makes it possible to use novel models of care to increase treatment uptake within prisons. We estimate the average non-drug cost of initiating a prisoner on treatment using real world data from the State-wide Hepatitis Program (SHP) in Victoria, Australia - a coordinated nurse-led model of care. METHODS: Data were considered from prisoners presenting to the SHP (following antibody-positive diagnosis) during the evaluation period, November 2015 to December 2016. All costs associated with the SHP were estimated, including staffing salaries, medical tests, pharm..View full abstract
Awarded by Medical Research Council of Australia (NHMRC)
This work was supported by Medical Research Council of Australia (NHMRC) [Partnership grant 1116161, Program grant 1132902].